Caliway Biopharmaceuticals (6919) Q2 2026 earnings summary

Executive summary

• H1 2026 net loss narrowed to NT$330.270m from NT$424.378m; comprehensive loss was NT$372.902m.

• Revenue remained small at NT$3.568m for H1, entirely from Taiwan health-food sales; operations are evaluated as one segment.

• Auditors issued a qualified review conclusion because certain non-significant subsidiaries were not independently reviewed.

Financial highlights

• H1 revenue NT$3.568m vs NT$12.212m YoY; Q2 revenue NT$3.566m vs NT$12.212m.

• H1 gross profit NT$2.328m vs NT$8.186m; operating expenses rose to NT$511.244m from NT$393.249m, and operating loss widened to NT$508.916m from NT$385.063m.

• H1 net loss improved to NT$330.270m from NT$424.378m; Q2 net loss was NT$222.516m vs NT$248.813m.

• H1 non-operating income was NT$178.646m, including NT$160.778m interest income and NT$17.968m net other gains; prior-year period had NT$39.315m net non-operating expense.

Outlook and guidance

• The group is evaluating IFRS 18, effective for annual periods beginning January 1, 2028; the standard adds an operating-profit subtotal, management performance measure disclosures and greater disaggregation.